MedTrace Logo

Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region

NCT07387211 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2484

Last updated 2026-02-04

No results posted yet for this study

Summary

The aim of the study is to find the proportion of people in the population of the Olomouc Region with the presence of IgG (or IgM) antibodies against the S and N antigens of the SARS-CoV-2 virus, therefore people who have already encountered the SARS-CoV-2 virus with manifest antibody formation, or people who have undergone vaccination against COVID-19.

Conditions

Interventions

PROCEDURE

Blood sampling

Venous blood sampling three times on three visits of the study.

PROCEDURE

Gargle sampling

Gargle sampling using GARGTEST sampling kit on three visits of the study and also gargle self-sampling using GARGTEST sampling kit at 14-day intervals between the study visits.

OTHER

Questionnaire completion

Patient will complete questionnaire on each visit on SARS-CoV-2 infections and vaccinations

DIAGNOSTIC_TEST

Body temperature measurement

Body temperature will be measured by healthcare professional at each visit to exclude patients with acute infection.

Sponsors & Collaborators

  • Palacky University

    collaborator OTHER

  • University Hospital Olomouc

    collaborator OTHER

  • The Institute of Molecular and Translational Medicine, Czech Republic

    lead OTHER

Principal Investigators

  • Marian Hajduch, MD, PhD · Palacky University Olomouc

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-18
Primary Completion
2022-10-13
Completion
2022-10-13

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07387211 on ClinicalTrials.gov